目的　观察诺维本治疗恶性胸腔积液的疗效 ,探讨与生物化学联合疗效。方法　把患者随机分为诺维本治疗组 (2 6例 )、重组人白细胞介素 - 2治疗组 (2 3例 )及两药联合治疗组 (2 4例 )。均行胸腔闭式引流术 ,排尽胸水 ,注入诺维本 30 mg/ m2 ,重组人白细胞介素 - 2 2 0 0万 IU/ m2 ,用 2 %利多卡因 5～ 10 ml溶解、稀释 ,夹管 ,患者变动体位 ,2 h后松开引流管持续引流 ,当胸水引流量 <5 0 ml/ d经胸透或超声证实基本无胸水后拔管。结果　诺维本组有效率 88.5 %、重组人白细胞介素 - 2组有效率 5 2 .2 % ,两组疗效差异有显著意义 ,而联合用药组有效率 91.7% ,与诺维本组疗效差异无显著意义。三组副作用无明显差异 (P>0 .0 5 )。结论　诺维本治疗恶性胸腔积液效果显著 ,而与生物化学联合治疗未进一步提高疗效 Objective To observe the curative effect of noviben in the treatment of malignant pleural effusion and to explore the combined effect with biochemistry. Methods The patients were randomly divided into two groups: nocturnal treatment group (26 cases), recombinant interleukin - 2 treatment group (23 cases) and combination therapy group (24 cases). All patients underwent closed thoracic drainage and drainage of pleural effusion. The patients were injected with noviban 30 mg / m2, recombinant human interleukin-2200 IU / m2, dissolved and diluted with 5 ~ 10 ml lidocaine 2% Pinch tube, patient position changes, release the drainage tube after 2 h continuous drainage, when pleural effusion <50 ml / d confirmed by the chest or ultrasound without end pleural effusion extubation. Results The effective rate of Novobibain was 88.5%, and the effective rate of recombinant interleukin-2 was 52.2%. There was significant difference between the two groups. The effective rate of combination group was 91.7% No significant meaning. There was no significant difference between the three groups (P> 0.05). Conclusion Noviben significant effect of treatment of malignant pleural effusion, and combined with biochemistry did not further improve the efficacy